



**LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES  
CORE PHARMACY & THERAPEUTICS COMMITTEE**

March 15, 2019

TO: DHS Core P&T Committee  
MHLA Clinics

FROM: Jeffrey Guterman, M.D.  
Jean Pallares, Pharm.D.  
Chairs, DHS Core Pharmacy and Therapeutics Committee

RE: March 2019 MHLA Formulary Decisions

**MY HEALTH LA FORMULARY**

<b>Restriction Change</b>	
<b>Drug Product</b>	<b>Comments</b>
Digoxin 0.125mg, 0.25mg Oral Tablets	Restricted to generic only (Lanoxin® adjudication allowed until 4/15/2019 for transition)
Hydroxychloroquine 200mg Oral Tablets	Restricted to generic only (Plaquenil® adjudication allowed until 4/15/2019 for transition)
Levothyroxine 25mcg, 50mcg, 75mcg, 88mcg, 100mcg, 112mcg, 125mcg, 137mcg, 150mcg, 175mcg, 200mcg Oral Tablets	Restricted to generic only
Norethindrone 0.35mg Oral Tablet	No Restrictions

This document contains confidential information intended for Los Angeles County Health Professionals and employees only. Unintended recipients may not disclose, copy, distribute, or take any action based on this document. This information is not to be disclosed to pharmaceutical representatives, press, or other outside agents.